DPM3-CDG is a very rare inherited condition that usually starts in infancy or childhood and affects muscles most strongly. Early signs of DPM3-CDG can include low muscle tone, muscle weakness, delayed motor milestones, and trouble with feeding or growth. Not everyone will have the same experience. Many people with DPM3-CDG live with lifelong movement problems, and some also develop heart weakness or learning difficulties. Treatment for DPM3-CDG focuses on supportive care such as physical therapy, nutrition support, and regular heart and breathing checks, because severe heart or breathing problems can sometimes become life-threatening.
How many people live with Dpm3-cdg?
DPM3-CDG is so rare that no reliable worldwide count has been published; rare-disease references describe only a handful of reported cases rather than a true global estimate (Orphanet, 2024). A separate U.S. estimate has not been published either, so the number of people living with DPM3-CDG in the United States is also unknown (Orphanet, 2024).
Overview
Dpm3-cdgSymptoms
DPM3-CDG often causes weak muscle tone, delayed motor skills, and muscle weakness. Many people with DPM3-CDG also have an enlarged heart or heart muscle disease, though features and severity can vary.
Outlook and prognosis
Dpm3-cdg is lifelong, but the outlook varies widely. Many living with Dpm3-cdg need ongoing support for muscle weakness, movement, learning, or heart problems. Prognosis depends on which body systems are affected and how severe those problems are.
Causes and risk factors
DPM3-CDG is caused by harmful changes in the DPM3 gene, usually inherited from both parents. It is present from before birth; lifestyle and environmental factors do not cause DPM3-CDG, but they can affect complications and day-to-day health.
Genetic influences
Genetics are central to Dpm3-cdg, because it is caused by changes in the DPM3 gene. These genetic variations disrupt a key cell process, and the exact variant can help confirm the diagnosis and sometimes guide family testing.
Diagnosis
Diagnosis of DPM3-CDG usually starts with clinical features, symptoms, and blood tests that suggest a congenital disorder of glycosylation. Doctors then confirm the genetic diagnosis of DPM3-CDG with genetic tests that look for changes in the DPM3 gene.
Treatment and drugs
Treatment for DPM3-CDG focuses on day-to-day needs. Many living with DPM3-CDG benefit from physical therapy, feeding and nutrition support, and medicines if seizures occur. Regular heart and muscle checks help guide care as symptoms change.
Symptoms
DPM3-CDG often affects muscles first, so everyday tasks may take more effort than expected. Early features of DPM3-CDG can include low muscle tone, delayed motor milestones, and weakness that makes sitting up, walking, or climbing stairs hard. Some people also have heart muscle problems, and learning or development may be mildly affected. Features vary from person to person and can change over time.
Babies with low muscle tone may feel floppy when held and may tire easily during feeding or play. As children grow, this can affect posture and make physical activity harder.
Rolling, sitting, standing, and walking may happen later than expected. Many people with DPM3-CDG need more time and therapy support to build strength and motor skills.
Weakness often affects the hips and shoulders most, so getting up from the floor, lifting the arms, or climbing stairs can be difficult. Some people also tire quickly with walking or other everyday activity.
Some people develop a weakened or enlarged heart muscle, which can lead to poor stamina, shortness of breath, or swelling. Doctors call this cardiomyopathy, and it needs regular follow-up because it can become serious.
How people usually first notice Dpm3-cdg?
Because DPM3-CDG is a genetic condition, it is usually first noticed in infancy or early childhood, often when a baby seems unusually floppy, has feeding difficulties, or is slower than expected to reach motor milestones like sitting, standing, or walking. As children grow, many living with DPM3-CDG are first brought to medical attention because of muscle weakness, delayed development, or sometimes signs of heart muscle problems, which can prompt more testing. The first signs of DPM3-CDG can vary from one child to another, but families and doctors often recognize it through this early pattern of low muscle tone, movement delays, and related muscle or heart concerns.
Types of Dpm3-cdg
No distinct types of Dpm3-cdg are widely recognized.
Can I slow down the onset of symptoms?
No, at this time there is no good evidence that lifestyle changes or medicines can meaningfully delay the start of symptoms in DPM3-CDG, because it is a very rare inherited condition that often begins early in life. Research is still ongoing, but right now care is focused on early checkups and support for problems with muscles, the heart, movement, and development rather than on preventing symptoms from starting. Even though this cannot promise a later onset, staying closely connected with a specialist team can help problems be found and treated sooner.
What genetics can tell you about symptoms
In DPM3-CDG, genetics can give some clues about symptoms, but they cannot predict everything for one individual. Different changes in the DPM3 gene are linked with a range of patterns, from mainly muscle weakness and trouble with movement to more widespread problems such as developmental delay or heart involvement, and some changes may be associated with earlier onset or more severe disease than others. Because this condition is very rare and only a small number of families have been described, genetic results are most helpful for confirming the diagnosis and giving a general sense of possible severity, rather than precisely forecasting which symptoms someone will have.
Causes and risk factors
For families living with DPM3-CDG, the condition is caused by changes in the DPM3 gene. In most cases, a child inherits one changed copy from each parent, so the main risk factors for DPM3-CDG are a family history of the condition and having two carrier parents. Parents who are related by blood, such as cousins, may have a higher chance of carrying the same rare gene change. Lifestyle, diet, infections, or something done during pregnancy are not known to cause DPM3-CDG, though general health can affect how symptoms show up day to day. Genetic testing can sometimes clarify your personal risk and help relatives understand carrier status.
What are the most common causes or risk factors?
The main cause of DPM3-CDG is inheriting harmful changes in both copies of the DPM3 gene, with one changed copy passed down from each parent. The biggest risk factors are having parents who both carry a changed DPM3 gene, a family history of the condition, or parents who are blood relatives, which makes it more likely they carry the same rare gene change. There are no known lifestyle, diet, or environmental causes for this condition.
Environmental and biological risk factors
DPM3-CDG is a very rare condition that starts before birth, and there are no well-established environmental or non-genetic biological risk factors known to make it more likely. Unlike some other congenital conditions, current evidence does not link DPM3-CDG to parental age, common pregnancy illnesses, medications, diet, or everyday exposures. If you are looking for environmental and biological risk factors for DPM3-CDG, the main point is that none have been clearly confirmed so far.
Researchers have not identified any environmental exposures or non-genetic biological factors that clearly increase the chance of DPM3-CDG. Based on current knowledge, there is no proven link with routine pregnancy exposures, infections, or other common body-based risks.
Genetic risk factors
In DPM3-CDG, the key genetic cause is a change in the DPM3 gene. The condition usually develops when a child inherits two nonworking copies of this gene, one from each biologic parent. Some risk factors are inherited through our genes. For many families, the main genetic risk factors for DPM3-CDG are carrier parents, family history, and parents who are biologically related.
DPM3 gene: DPM3-CDG is caused by harmful changes in the DPM3 gene. These changes disrupt an important cell process that helps many proteins work as they should.
Recessive inheritance: DPM3-CDG usually follows an autosomal recessive pattern of inheritance. This means a child typically needs to inherit two altered copies of DPM3 to have the condition.
Carrier parents: When both biologic parents carry one altered DPM3 copy, each pregnancy has a 1 in 4, or 25%, chance of DPM3-CDG. There is also a 1 in 2, or 50%, chance that the child will be a healthy carrier.
Family history: A known case of DPM3-CDG in the family can mean relatives have a higher chance of carrying the same gene change. An affected brother or sister is often an important clue when doctors assess genetic risk.
Related parents: If biologic parents are related by blood, they are more likely to carry the same rare DPM3 change. This raises the chance that a child could inherit two altered copies of the gene.
Lifestyle risk factors
DPM3-CDG is an inherited condition, so lifestyle habits do not cause it. Still, how lifestyle affects DPM3-CDG can matter for muscle weakness, fatigue, mobility, swallowing, and heart-related complications in people who have this disorder. The most relevant lifestyle risk factors for DPM3-CDG are the daily habits that can either strain or support muscle and overall function.
Too little movement can worsen deconditioning, joint stiffness, and loss of stamina in people with DPM3-CDG. Regular, carefully paced activity or physiotherapy-based exercise may help maintain mobility and muscle function without overloading already weak muscles.
Intense exercise, repeated heavy lifting, or pushing through severe fatigue can aggravate muscle pain and functional decline in DPM3-CDG. Energy pacing, rest breaks, and adjusting activity to symptoms may reduce crashes and improve day-to-day endurance.
Poor calorie or protein intake can make muscle weakness and fatigue more noticeable in DPM3-CDG. If chewing or swallowing is difficult, tailored meals and dietitian guidance may help maintain strength, weight, and safer feeding.
Eating too quickly, taking large bites, or lying down right after meals can increase choking or aspiration risk when DPM3-CDG affects bulbar or swallowing muscles. Slower eating, texture changes, and upright posture during meals may improve safety and comfort.
Risk prevention
DPM3-CDG is a rare inherited condition, so there is no known way to prevent the condition itself if a child is born with the gene change. For many living with DPM3-CDG, prevention means lowering the risk of complications and helping the body cope with muscle weakness, movement problems, or heart-related issues that can come with it. Prevention is flexible—it adapts to your life and health background. Early, regular care can also make it easier to catch changes before they become more serious.
If DPM3-CDG runs in your family, genetic counseling can help you understand the chance of having an affected child. It can also explain testing options before or during pregnancy in clear, practical terms.
Ongoing visits with specialists can help track muscle strength, movement, and heart health in people with DPM3-CDG. This may help spot early symptoms of DPM3-CDG sooner and guide treatment before problems build up.
Tailored exercise and physical therapy may help protect mobility, balance, and joint movement. For many, this can mean staying steadier on stairs, getting up from a chair more easily, or reducing falls.
Some people with DPM3-CDG may need regular heart tests to watch for strain or weakening of the heart muscle. Finding heart changes early can lower the risk of serious complications and support safer daily activity.
Can you prevent Dpm3-cdg?
No. DPM3-CDG is a rare inherited condition caused by a change in a gene, so there is no proven way to prevent it in someone who is born with it. If it runs in your family, talking with a genetics specialist before pregnancy may help you understand the chance of it happening again and what testing options are available.
Transmission
DPM3-CDG is not infectious, so it does not spread from one person to another through touch, kissing, coughing, sex, blood, or shared food.
Instead, the genetic transmission of DPM3-CDG usually follows an autosomal recessive pattern, which means a child inherits one changed DPM3 gene from each parent. Many parents are healthy carriers and do not know they carry the gene change because one working copy is often enough for normal health. If both parents are carriers, each pregnancy has a 25% chance, or 1 in 4, of DPM3-CDG.
When to test your genes
For DPM3-CDG, genetic testing is usually considered when a child has signs that suggest a congenital disorder of glycosylation, such as low muscle tone, developmental delay, muscle weakness, or unexplained neurologic findings. It is also important if there is a known family history or an affected sibling, because results can confirm the diagnosis and guide care and family planning.
Diagnosis
DPM3-CDG is usually diagnosed by putting together a child’s symptoms, exam findings, and a small number of targeted tests. Many living with DPM3-CDG come to medical attention because of low muscle tone, delayed motor skills, muscle weakness, or heart problems that do not have an obvious cause. Getting a diagnosis is often a turning point toward answers and support. Because this is a very rare inherited condition, the diagnosis of DPM3-CDG is often confirmed with genetic testing.
Doctors look at the overall pattern of signs, such as weak muscles, low muscle tone, delayed development, and sometimes an enlarged or weakened heart. In a rare condition like DPM3-CDG, this combination can raise suspicion that the problem affects how the body processes certain proteins.
A detailed family and health history can help show whether similar symptoms have appeared in relatives or whether there may be an inherited condition. DPM3-CDG is genetic, so this background can guide the choice of further testing.
Blood tests may show muscle injury markers, such as a high creatine kinase level, and can help check for liver, heart, or other organ involvement. These results do not prove DPM3-CDG on their own, but they help build the clinical picture and rule out more common causes.
An electrocardiogram and an ultrasound of the heart may be done if there are signs of cardiomyopathy, breathing difficulty, poor feeding, or tiring easily. These tests help doctors see whether DPM3-CDG is affecting heart function.
How is Dpm3-cdg diagnosed?
Doctors usually suspect DPM3-CDG from the pattern of health problems a person has, such as muscle weakness, delayed development, or heart problems, together with blood tests that show the body is not attaching sugar parts to proteins in the usual way. A common first test looks at a blood protein called transferrin, and doctors may also do other checks, such as heart tests or brain scans, depending on the symptoms. The diagnosis is usually confirmed with genetic testing that looks for a change in the DPM3 gene.
Stages of Dpm3-cdg
Dpm3-cdg does not have defined progression stages. This is because it is a rare genetic condition that is usually described by the pattern and severity of symptoms a person has, rather than by a predictable step-by-step worsening over time. Often the process begins when you notice changes in daily life, such as delayed motor milestones, muscle weakness, or heart-related symptoms, and doctors then look at the medical history, physical exam, blood tests, and sometimes heart and muscle testing. Genetic testing is usually needed to confirm the diagnosis, and follow-up care focuses on checking how symptoms are affecting day-to-day life rather than tracking formal stages, including watching for early symptoms of Dpm3-cdg that may change with growth.
Outlook and prognosis
The outlook for people with DPM3-CDG is variable and depends largely on which organs are affected and how severe the muscle, brain, or heart involvement is. Reported cases are very rare, but some individuals have had a relatively stable course with longstanding muscle weakness and developmental difficulties, while others have shown more serious neurologic or multisystem disease. When cardiomyopathy, severe seizures, or major feeding and breathing problems are present, the prognosis is generally poorer and complications can be life-threatening. Because so few patients have been described, there is no reliable life-expectancy estimate, and published mortality data are limited. Early recognition, supportive multidisciplinary care, and close monitoring of cardiac, respiratory, and neurologic function may improve quality of life and help reduce preventable complications.
Long-term effects
For many living with DPM3-CDG, the biggest long-term effects are usually related to muscles, movement, and overall development. Long-term effects vary widely, and because DPM3-CDG is very rare, the outlook can differ a lot from one person to another. Some people have a milder course, while others develop more significant physical disability or heart involvement over time.
Ongoing muscle weakness is one of the main long-term features of DPM3-CDG. This can affect daily tasks such as climbing stairs, standing up from the floor, lifting objects, or walking longer distances.
Over time, reduced strength can lead to delayed motor skills, trouble with balance, and increasing difficulty with mobility. Many living with DPM3-CDG may need more physical support as they get older, especially if walking becomes harder.
Some people with DPM3-CDG have long-term developmental delay or learning difficulties. In day-to-day life, this may mean needing extra help with speech, schoolwork, planning, or independent living.
Some reported cases include heart muscle disease, which can become a serious long-term effect of DPM3-CDG. When this happens, people may tire easily, have reduced exercise tolerance, or develop signs of heart failure over time.
How is it to live with Dpm3-cdg?
Living with DPM3-CDG often means managing a condition that can affect muscles, movement, and development from early in life, although the day-to-day experience can vary widely from one person to another. Many living with DPM3-CDG need ongoing physical, developmental, and medical support, and families may build daily routines around therapies, mobility needs, fatigue, and regular follow-up visits, especially if heart or muscle problems are part of the picture. This can place emotional, practical, and financial demands on the people around them, but with coordinated care, adapted supports, and a strong network, many families find ways to create stability and help the child or adult participate as fully as possible in everyday life.
Treatment and drugs
Treatment for Dpm3-cdg focuses on managing symptoms and supporting day-to-day function, because there is currently no cure that fixes the underlying genetic change. The best plan depends on which parts of the body are affected, but many people with Dpm3-cdg need care from several specialists, along with physical, occupational, or speech therapy to help with movement, strength, feeding, or communication. Supportive care can make a real difference in how you feel day to day, and medicines may be used to treat specific problems such as seizures, heart-related symptoms, or digestive issues if they occur. Because this is a rare condition, treatment is usually individualized, and regular follow-up helps doctors adjust care as needs change over time.
Can you cure Dpm3-cdg?
No, there is currently no cure for DPM3-CDG. Because it is a rare inherited condition, treatment focuses on managing symptoms, supporting movement and development, and watching for problems such as muscle weakness or heart issues. Regular care can help many living with DPM3-CDG get the right therapies, medicines, and day-to-day support.
Non-drug treatment
Daily care for people with DPM3-CDG usually focuses on building strength, supporting development, and making eating, communication, and movement safer and easier. Because DPM3-CDG can affect each person differently, non-drug treatment is usually tailored to the symptoms and how they change over time. Not every approach works the same way, so many living with DPM3-CDG benefit from a team that may include physical, occupational, speech, and nutrition specialists.
Physical therapy can help with low muscle tone, weakness, balance problems, and delayed motor skills. For many, this can mean practicing sitting, standing, walking, and safe transfers in ways that fit daily life.
Occupational therapy helps people with DPM3-CDG work on hand use, play, dressing, and other everyday tasks. It can also suggest simple tools or positioning changes that make activities less tiring and safer.
Speech and language therapy can support communication, whether a child is learning first words or needs other ways to express needs. If early symptoms of DPM3-CDG include feeding or mouth-motor problems, the same team may also help with chewing and swallowing skills.
Feeding therapy and nutrition support can help if meals take a long time, weight gain is poor, or swallowing is difficult. This may include texture changes, paced feeding, and close follow-up to support growth and reduce choking risk.
Your genes may have an impact on how drugs work for you
Because DPM3-CDG is a very rare inherited condition, there is not much clear evidence that it changes how people respond to most everyday medicines in a predictable way. In practice, treatment is usually guided more by the person’s symptoms, muscle weakness, heart issues, and overall health than by known medicine-response gene testing. If someone living with DPM3-CDG needs a new medicine, their care team may still watch a little more closely for side effects or how well it works, especially because rare genetic conditions can affect the body in ways that are hard to predict.
Pharmacological treatments
Daily care for DPM3-CDG usually focuses on treating the problems it causes rather than correcting the underlying gene change. There is no approved medicine that targets DPM3-CDG itself, so treatment is tailored to symptoms such as seizures, heart weakness, muscle stiffness, pain, or feeding problems. Not everyone responds to the same medication in the same way. For many families looking into treatment for DPM3-CDG, this means a mix of medicines may be used over time as needs change.
If seizures are part of DPM3-CDG, doctors often use standard anti-seizure medicines such as levetiracetam, valproate, or clobazam. The choice depends on seizure type, age, and side effects.
Some people with DPM3-CDG develop cardiomyopathy or heart failure, and medicines such as ACE inhibitors, beta-blockers, and diuretics may help the heart work more efficiently. Examples include enalapril, carvedilol, and furosemide.
When tight muscles or painful stiffness limit walking, dressing, or comfort, medicines such as baclofen or diazepam may be used. Dosing may be increased or lowered gradually to balance benefit with sleepiness or weakness.
Muscle pain or nerve-like discomfort may sometimes be treated with acetaminophen, ibuprofen, gabapentin, or pregabalin, depending on the pattern of symptoms. These medicines do not treat the cause of DPM3-CDG, but they may improve day-to-day comfort.
Genetic influences
DPM3-CDG happens because of disease-causing changes in the DPM3 gene. This gene helps the body make a substance needed to attach certain sugar chains to proteins, so when it does not work properly, several organs and tissues can be affected. DPM3-CDG is inherited in an autosomal recessive pattern, which means a child must inherit one changed copy of DPM3 from each parent. A carrier means you hold the gene change but may not show symptoms. When both parents are carriers, each pregnancy has a 25% (1 in 4) chance of DPM3-CDG, a 50% (1 in 2) chance that the child will be a carrier, and a 25% (1 in 4) chance of inheriting two working copies. Genetic testing for DPM3-CDG can confirm the diagnosis and help families understand who else may be a carrier or at risk in future pregnancies.
Is Dpm3-cdg genetic?
Genetics are central to Dpm3-cdg, because it is caused by changes in the DPM3 gene. These genetic variations disrupt a key cell process, and the exact variant can help confirm the diagnosis and sometimes guide family testing.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a common, normal part of human biology. Most have no direct effect on health and are simply part of the natural diversity seen among people. For many genes, carrying a variant associated with a condition suggests a possible link rather than a definitive diagnosis, especially when several genes and environmental factors are involved. In some cases, however, a single well-characterized variant in a specific gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
For many living with Dpm3-cdg, treatment is shaped by the symptoms that affect daily life most, such as muscle weakness, feeding trouble, seizures, or heart problems. Finding the change in the DPM3 gene helps confirm the diagnosis and can help doctors plan monitoring and supportive care, including physical and occupational therapy, nutrition support, seizure medicines when needed, and regular heart follow-up. Unlike some conditions where a genetic result helps match someone to a specific drug, there is currently no proven medicine that corrects the underlying gene change in Dpm3-cdg itself. Genetics is only one factor, and age, overall health, the exact symptoms, and other medicines also matter when choosing treatment. Because Dpm3-cdg is rare and can vary from one person to another, treatment for Dpm3-cdg is usually adjusted over time based on how someone is doing rather than by a fixed medication plan.
Interactions with other conditions
For many living with DPM3-CDG, the biggest concern is not just the condition itself but how it can overlap with problems affecting the muscles, heart, and sometimes breathing or feeding. Weak muscles may make it harder to recover from common illnesses such as chest infections, and if heart muscle weakness is present, extra strain from fever, dehydration, or another illness can make symptoms more noticeable. Doctors call it a comorbidity when two conditions occur together, and in DPM3-CDG this may include developmental difficulties, trouble gaining weight, or heart disease that needs its own monitoring and treatment. Because DPM3-CDG is rare and symptoms can vary, interactions can look very different from person to person.
In day-to-day life, this can mean one issue makes another harder to manage, such as fatigue worsening physical therapy progress or feeding problems affecting strength and growth. If early symptoms of DPM3-CDG include muscle weakness or delayed motor milestones, doctors may also look closely for heart involvement and other related health concerns so care can be coordinated early. When more than one specialist is involved, regular follow-up helps catch changes sooner and reduces the chance that one problem will be missed because it looks like another.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Dpm3-cdg?
Because DPM3-CDG can cause low muscle tone, muscle weakness, and delayed development, it can look a lot like other congenital disorders of glycosylation, some forms of muscular dystrophy, and mitochondrial disease, which affects how cells make energy. In babies and children, doctors may also think about spinal muscular atrophy or cerebral palsy, since these can also cause “floppiness,” trouble gaining motor skills, and movement problems.
History
For families living with Dpm3-cdg, the story often begins with muscle weakness, delayed motor milestones, or heart problems that do not seem to fit a more common diagnosis. A baby may seem unusually floppy, or a child may tire quickly when trying to stand, climb stairs, or keep up with other children. Because these signs can overlap with several nerve, muscle, and metabolic conditions, early symptoms of Dpm3-cdg were not recognized right away as part of one distinct disorder.
The broader group of conditions it belongs to, called congenital disorders of glycosylation, started coming into clearer focus in the late 20th century as laboratory testing improved. Doctors gradually realized that some children with unexplained developmental issues, low muscle tone, and problems affecting more than one body system were not dealing with separate illnesses, but with disorders linked by the same basic cell process. In recent decades, awareness has grown, and this helped researchers sort very rare forms like Dpm3-cdg from better known types in the same family.
Dpm3-cdg itself was described much later than the first recognized glycosylation disorders. Early reports identified only a small number of affected people, which is common with very rare conditions. Those first case descriptions were important because they showed a repeated pattern, especially involving muscle disease and, in some people, heart involvement, helping doctors recognize that this was a specific condition rather than an unusual one-off finding.
As genetic testing became more available, researchers were able to connect the clinical pattern to an underlying genetic cause and place Dpm3-cdg more accurately within the CDG group. That changed the way the condition was understood: instead of being seen mainly as an unexplained muscle disorder, it became clear that it affects a basic pathway many cells use to modify proteins. Even now, much of what doctors know comes from a small number of published cases, so the medical picture is still growing.
Knowing the condition’s history helps explain why diagnosis can still take time today. For many living with Dpm3-cdg, the condition has moved from being something doctors rarely recognized to one that can be identified more clearly with modern testing, earlier specialist input, and a better understanding of its pattern of symptoms.